The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

George D. Demetri

Ludwig Center at Dana-Farber Cancer Institute

Harvard Medical School

Boston

MA 02215

USA

[email]@partners.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Ludwig Center at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. 2002 - 2013
  • Center for Sarcoma and Bone Oncology, Ludwig Center at Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute, 450 Brookline Ave., USA. 2009 - 2012
  • Dana-Farber Cancer Institute, Boston, MA 02115, USA. 2001 - 2011
  • Ludwig Center, Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute, D1212, USA. 2009

References

  1. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Demetri, G.D., Reichardt, P., Kang, Y.K., Blay, J.Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., Badalamenti, G., Blackstein, M., Le Cesne, A., Schöffski, P., Maki, R.G., Bauer, S., Nguyen, B.B., Xu, J., Nishida, T., Chung, J., Kappeler, C., Kuss, I., Laurent, D., Casali, P.G. Lancet (2013) [Pubmed]
  2. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Demetri, G.D., Garrett, C.R., Schöffski, P., Shah, M.H., Verweij, J., Leyvraz, S., Hurwitz, H.I., Pousa, A.L., Le Cesne, A., Goldstein, D., Paz-Ares, L., Blay, J.Y., McArthur, G.A., Xu, Q.C., Huang, X., Harmon, C.S., Tassell, V., Cohen, D.P., Casali, P.G. Clin. Cancer Res. (2012) [Pubmed]
  3. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Demetri, G.D. Semin. Oncol. (2011) [Pubmed]
  4. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. Demetri, G.D., Wang, Y., Wehrle, E., Racine, A., Nikolova, Z., Blanke, C.D., Joensuu, H., von Mehren, M. J. Clin. Oncol. (2009) [Pubmed]
  5. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Demetri, G.D., Casali, P.G., Blay, J.Y., von Mehren, M., Morgan, J.A., Bertulli, R., Ray-Coquard, I., Cassier, P., Davey, M., Borghaei, H., Pink, D., Debiec-Rychter, M., Cheung, W., Bailey, S.M., Veronese, M.L., Reichardt, A., Fumagalli, E., Reichardt, P. Clin. Cancer Res. (2009) [Pubmed]
  6. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Demetri, G.D., Lo Russo, P., MacPherson, I.R., Wang, D., Morgan, J.A., Brunton, V.G., Paliwal, P., Agrawal, S., Voi, M., Evans, T.R. Clin. Cancer Res. (2009) [Pubmed]
  7. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. Demetri, G.D., Chawla, S.P., von Mehren, M., Ritch, P., Baker, L.H., Blay, J.Y., Hande, K.R., Keohan, M.L., Samuels, B.L., Schuetze, S., Lebedinsky, C., Elsayed, Y.A., Izquierdo, M.A., Gómez, J., Park, Y.C., Le Cesne, A. J. Clin. Oncol. (2009) [Pubmed]
  8. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Demetri, G.D., Heinrich, M.C., Fletcher, J.A., Fletcher, C.D., Van den Abbeele, A.D., Corless, C.L., Antonescu, C.R., George, S., Morgan, J.A., Chen, M.H., Bello, C.L., Huang, X., Cohen, D.P., Baum, C.M., Maki, R.G. Clin. Cancer Res. (2009) [Pubmed]
  9. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. Demetri, G.D. J. Clin. Invest. (2007) [Pubmed]
  10. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Demetri, G.D., van Oosterom, A.T., Garrett, C.R., Blackstein, M.E., Shah, M.H., Verweij, J., McArthur, G., Judson, I.R., Heinrich, M.C., Morgan, J.A., Desai, J., Fletcher, C.D., George, S., Bello, C.L., Huang, X., Baum, C.M., Casali, P.G. Lancet (2006) [Pubmed]
  11. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. Garcia-Carbonero, R., Supko, J.G., Manola, J., Seiden, M.V., Harmon, D., Ryan, D.P., Quigley, M.T., Merriam, P., Canniff, J., Goss, G., Matulonis, U., Maki, R.G., Lopez, T., Puchalski, T.A., Sancho, M.A., Gomez, J., Guzman, C., Jimeno, J., Demetri, G.D. J. Clin. Oncol. (2004) [Pubmed]
  12. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Demetri, G.D., Gabrilove, J.L., Blasi, M.V., Hill, R.J., Glaspy, J. Clin. Breast Cancer (2002) [Pubmed]
  13. ET-743: the US experience in sarcomas of soft tissues. Demetri, G.D. Anticancer. Drugs (2002) [Pubmed]
  14. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Demetri, G.D. Hematol. Oncol. Clin. North Am. (2002) [Pubmed]
  15. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Demetri, G.D. Eur. J. Cancer (2002) [Pubmed]
  16. Targeted approaches for the treatment of thrombocytopenia. Demetri, G.D. Oncologist (2001) [Pubmed]
 
WikiGenes - Universities